Cargando…
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T ce...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405826/ https://www.ncbi.nlm.nih.gov/pubmed/37554324 http://dx.doi.org/10.3389/fimmu.2023.1230135 |
_version_ | 1785085618942902272 |
---|---|
author | Feng, Chong Zhang, Lening Chang, Xin Qin, Dongliang Zhang, Tao |
author_facet | Feng, Chong Zhang, Lening Chang, Xin Qin, Dongliang Zhang, Tao |
author_sort | Feng, Chong |
collection | PubMed |
description | The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T cells, resulting in tumor immune escape. The therapeutic strategy of targeting PD-1/PD-L1 involves blocking this binding and restoring the tumor-killing effect of immune cells. However, in clinical settings, a relatively low proportion of cancer patients have responded well to PD-1/PD-L1 blockade, and clinical outcomes have reached a bottleneck and no substantial progress has been made. In recent years, PD-L1 post-translation modifications (PTMs) have gradually become a hot topic in the field of PD-L1 research, which will provide new insights to improve the efficacy of current anti-PD-1/PD-L1 therapies. Here, we summarized and discussed multiple PTMs of PD-L1, including glycosylation, ubiquitination, phosphorylation, acetylation and palmitoylation, with a major emphasis on mechanism-based therapeutic strategies (including relevant enzymes and targets that are already in clinical use and that may become drugs in the future). We also summarized the latest research progress of PTMs of PD-L1/PD-1 in regulating immunotherapy. The review provided novel strategies and directions for tumor immunotherapy research based on the PTMs of PD-L1/PD-1. |
format | Online Article Text |
id | pubmed-10405826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104058262023-08-08 Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy Feng, Chong Zhang, Lening Chang, Xin Qin, Dongliang Zhang, Tao Front Immunol Immunology The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor immunotherapy. PD-L1 is overexpressed on the surface of tumor cells and inhibits T cell activation upon binding to PD⁃1 on the surface of T cells, resulting in tumor immune escape. The therapeutic strategy of targeting PD-1/PD-L1 involves blocking this binding and restoring the tumor-killing effect of immune cells. However, in clinical settings, a relatively low proportion of cancer patients have responded well to PD-1/PD-L1 blockade, and clinical outcomes have reached a bottleneck and no substantial progress has been made. In recent years, PD-L1 post-translation modifications (PTMs) have gradually become a hot topic in the field of PD-L1 research, which will provide new insights to improve the efficacy of current anti-PD-1/PD-L1 therapies. Here, we summarized and discussed multiple PTMs of PD-L1, including glycosylation, ubiquitination, phosphorylation, acetylation and palmitoylation, with a major emphasis on mechanism-based therapeutic strategies (including relevant enzymes and targets that are already in clinical use and that may become drugs in the future). We also summarized the latest research progress of PTMs of PD-L1/PD-1 in regulating immunotherapy. The review provided novel strategies and directions for tumor immunotherapy research based on the PTMs of PD-L1/PD-1. Frontiers Media S.A. 2023-07-24 /pmc/articles/PMC10405826/ /pubmed/37554324 http://dx.doi.org/10.3389/fimmu.2023.1230135 Text en Copyright © 2023 Feng, Zhang, Chang, Qin and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Feng, Chong Zhang, Lening Chang, Xin Qin, Dongliang Zhang, Tao Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title | Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title_full | Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title_fullStr | Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title_full_unstemmed | Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title_short | Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy |
title_sort | regulation of post-translational modification of pd-l1 and advances in tumor immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405826/ https://www.ncbi.nlm.nih.gov/pubmed/37554324 http://dx.doi.org/10.3389/fimmu.2023.1230135 |
work_keys_str_mv | AT fengchong regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy AT zhanglening regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy AT changxin regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy AT qindongliang regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy AT zhangtao regulationofposttranslationalmodificationofpdl1andadvancesintumorimmunotherapy |